PL3846810T3 - Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie - Google Patents

Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie

Info

Publication number
PL3846810T3
PL3846810T3 PL19773583.0T PL19773583T PL3846810T3 PL 3846810 T3 PL3846810 T3 PL 3846810T3 PL 19773583 T PL19773583 T PL 19773583T PL 3846810 T3 PL3846810 T3 PL 3846810T3
Authority
PL
Poland
Prior art keywords
lasmiditan
migraine prevention
chronic nightly
dosing
nightly dosing
Prior art date
Application number
PL19773583.0T
Other languages
English (en)
Inventor
Robert Russell CONLEY
Gudarz Davar
Kirk Willis Johnson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68051892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3846810(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3846810T3 publication Critical patent/PL3846810T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
PL19773583.0T 2018-09-04 2019-09-03 Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie PL3846810T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04
PCT/US2019/049340 WO2020051137A1 (en) 2018-09-04 2019-09-03 Chronic nightly dosing of lasmiditan for migraine prevention

Publications (1)

Publication Number Publication Date
PL3846810T3 true PL3846810T3 (pl) 2024-03-18

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19773583.0T PL3846810T3 (pl) 2018-09-04 2019-09-03 Przewlekłe nocne dawkowanie lasmiditanu w celu zapobiegania migrenie

Country Status (36)

Country Link
US (1) US12138254B2 (pl)
EP (2) EP3846810B1 (pl)
JP (2) JP7321256B2 (pl)
KR (1) KR102649644B1 (pl)
CN (1) CN112638383A (pl)
AU (3) AU2019336667B2 (pl)
BR (1) BR112021002945A2 (pl)
CL (1) CL2021000529A1 (pl)
CO (1) CO2021002766A2 (pl)
CR (1) CR20210126A (pl)
DK (1) DK3846810T3 (pl)
DO (1) DOP2021000039A (pl)
EA (1) EA202190440A1 (pl)
EC (1) ECSP21015491A (pl)
ES (1) ES2967665T3 (pl)
FI (1) FI3846810T3 (pl)
HR (1) HRP20231587T1 (pl)
HU (1) HUE064519T2 (pl)
IL (1) IL281208B2 (pl)
JO (1) JOP20210033B1 (pl)
LT (1) LT3846810T (pl)
MA (1) MA53551B1 (pl)
MD (1) MD3846810T2 (pl)
MX (1) MX2021002474A (pl)
MY (1) MY199662A (pl)
PE (1) PE20211599A1 (pl)
PH (1) PH12021550448A1 (pl)
PL (1) PL3846810T3 (pl)
PT (1) PT3846810T (pl)
RS (1) RS64857B1 (pl)
SG (1) SG11202101530PA (pl)
SI (1) SI3846810T1 (pl)
TW (1) TWI826514B (pl)
UA (1) UA129587C2 (pl)
WO (1) WO2020051137A1 (pl)
ZA (1) ZA202100666B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR102448369B1 (ko) 2014-02-05 2022-09-28 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CZ288897A3 (cs) 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
JPH11513666A (ja) 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
BR9711273A (pt) 1996-08-28 1999-08-17 Lilly Co Eli 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
CA2268164A1 (en) 1996-10-08 1998-04-16 Yao-Chang Xu New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
WO2000000487A1 (en) 1998-06-30 2000-01-06 Eli Lilly And Company 5-ht1f agonists
AU1937300A (en) 1998-12-11 2000-06-26 Eli Lilly And Company Indole derivatives and their use as 5-HT1F agonists
WO2000047559A2 (en) 1999-02-10 2000-08-17 Eli Lilly And Company 5-ht1f agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
HUP0200245A2 (en) 1999-02-26 2002-06-29 Lilly Co Eli Furo[3,2-b]pyridines as 5-ht1f agonists and pharmaceutical compositions containing them and their use
WO2002006196A1 (en) 2000-07-13 2002-01-24 Merck Patent Gmbh Chiral compounds i
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
EP1581498A2 (en) 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
ES2388547T3 (es) 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
KR20070094754A (ko) 2004-12-01 2007-09-21 데브젠 엔브이 이온 채널, 특히 Ｋｖ 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
NZ596161A (en) 2009-04-02 2013-11-29 Colucid Pharmaceuticals Inc Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US11053214B2 (en) 2016-12-06 2021-07-06 Colucid Pharmaceuticals, Inc. Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
ES2967665T3 (es) 2024-05-03
EA202190440A1 (ru) 2021-06-24
MD3846810T2 (ro) 2024-04-30
TW202033197A (zh) 2020-09-16
CO2021002766A2 (es) 2021-03-19
PE20211599A1 (es) 2021-08-18
JOP20210033B1 (ar) 2024-04-18
JOP20210033A1 (ar) 2021-02-25
MA53551B1 (fr) 2023-11-30
ZA202100666B (en) 2024-09-25
JP2023156344A (ja) 2023-10-24
SG11202101530PA (en) 2021-03-30
NZ774400A (en) 2024-03-22
DOP2021000039A (es) 2021-03-31
CR20210126A (es) 2021-04-22
SI3846810T1 (sl) 2023-12-29
CN112638383A (zh) 2021-04-09
BR112021002945A2 (pt) 2021-05-11
US20210338655A1 (en) 2021-11-04
AU2019336667B2 (en) 2022-09-29
IL281208B1 (en) 2024-10-01
JP2021535913A (ja) 2021-12-23
AU2019336667A1 (en) 2021-03-11
EP4279132A3 (en) 2024-03-06
ECSP21015491A (es) 2021-04-29
DK3846810T3 (da) 2023-12-04
MY199662A (en) 2023-11-15
US12138254B2 (en) 2024-11-12
IL281208A (en) 2021-04-29
EP3846810A1 (en) 2021-07-14
MX2021002474A (es) 2021-08-24
MA53551A (fr) 2022-01-12
HUE064519T2 (hu) 2024-03-28
LT3846810T (lt) 2024-01-10
UA129587C2 (uk) 2025-06-11
KR102649644B1 (ko) 2024-03-21
FI3846810T3 (fi) 2023-12-15
AU2022291568A1 (en) 2023-02-02
AU2025201479A1 (en) 2025-03-20
WO2020051137A1 (en) 2020-03-12
TWI826514B (zh) 2023-12-21
EP4279132A2 (en) 2023-11-22
JP7543497B2 (ja) 2024-09-02
RS64857B1 (sr) 2023-12-29
EP3846810B1 (en) 2023-10-18
IL281208B2 (en) 2025-02-01
KR20210039419A (ko) 2021-04-09
HRP20231587T1 (hr) 2024-03-15
JP7321256B2 (ja) 2023-08-04
CA3111205A1 (en) 2020-03-12
PH12021550448A1 (en) 2021-09-27
PT3846810T (pt) 2023-12-14
CL2021000529A1 (es) 2021-08-13

Similar Documents

Publication Publication Date Title
IL281208A (en) Chronic nocturnal dosing of lasmiditan for migraine prevention
SG11202005583QA (en) Ex situ coating of chamber components for semiconductor processing
IL281939A (en) VAP-1 inhibitors
IL247364A0 (en) c5a inhibitors for the treatment of viral pneumonia
IL307850A (en) A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
HUE062460T2 (hu) TRPC6 inhibitorok
IL275457A (en) Spiro exo-aza inhibitors of the MENIN-MLL interaction
IL265342A (en) Use of pridofidine for the treatment of Rett syndrome
IL253854A0 (en) A polymorph of mebendazole for the treatment and prevention of tumors
PT3573620T (pt) Composições para o tratamento da hipertensão
IL272061A (en) Preparations for the treatment of stress-related disorders
IL281815A (en) VAP-1 inhibitors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL283627A (en) Improved transport of large materials
SG11201607473PA (en) Composition for maintaining efficacy of filler
GB2577661B (en) Determination of lithography effective dose uniformity
IL262111B1 (en) Monovalent inhibitors of hutnfr1 interaction
IL274974A (en) Preparations for the prevention or treatment of acute radiation syndrome
PT3250203T (pt) Composição para utilização crónica como composto para ganho de peso
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
KR102388028B9 (ko) 폴리펩타이드 전달용 조성물
IL263336A (en) Compounds for the treatment of symphysiolysis
IL274552A (en) Treatment of side effects of botulinum treatments
IL231047A0 (en) Inhibitors of leukotriene-mediated activity to prevent or alleviate side effects of chemotherapy